Getting back into old habits and posting too much so I'll try and get my thoughts for the day outta the way now.

The two biggest risk factors I see for Resverlogix in order are, #1 Finance and #2 Scientific.  And with the MD&A pushing the goal posts further out (to use Bear's turn of phrase) it strikes me that the scientific risk is lessening, as noted by San Fran and others. 

Far and away the biggest risk in my eyes is the lack of financing.  Is strikes me that we're likely getting very close to the covenant requirement of having $5 million in the bank.  As before with the previous loan, this financing from Third Eye is leveraged against basically all the company's intellectual property, most importantly Apabetalone.  

Obviously DM is almost certainly working on raising more money...he sure as heck better be.  And its not something that gets done with a call in the morning and finalization in the afternoon.  I have to assume that negotiations are in all overwhelming probability on-going and dang near constant. 

If we get news of another offering, obviously the pricing is predicated on where RVX is trading....so I'm thinking that Monday/Tuesday's funky trading could be the result of an upcoming offering. 

Now I'll go crawl back into my little hole and watch the trading.  Hopefully we get some excitment to the upside on this second to last day of Friday trading before Christmas (one more Friday and then Santa comes).